Analyses of visual field data collected at centers across England showed the average level of severity of vision loss at the time of glaucoma detection decreased—improved—over time. Still, the rate of improvement between 1998 and 2012 was only 0.1 dB per year.
Although infections caused by methicillin-resistant Staphylococcus aureus (MRSA) are a prominent concern for cataract surgeons, leading ophthalmologists discuss the pros and cons of performing universal MRSA screening to guide targeted prophylaxis.
Welcome to the latest installment of “Sight Lines,” a feature in which J.C. Noreika, MD, MBA, an ophthalmologist in Medina, OH, discusses trends in ophthalmology, medicine, and health care with key leaders in their fields. In this issue, Dr. Noreika talks with U.S. Sen. Sherrod Brown (D-OH).
Novaliq GmbH has reported positive phase I results with its clear cyclosporin solution eye drop formulation (CyclASol) in clinical development for patients with dry eye syndrome.
Valeant Pharmaceuticals International’s wholly owned subsidiary, Bausch + Lomb, and Nicox S.A. have announced positive top-line results from the pivotal phase III studies conducted with latanoprostene bunod (Vesneo, previously known as BOL-303259-X and NCX 116) for the reduction of IOP in patients with glaucoma or ocular hypertension.